CoChat

A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model

Open access
Resalat, Navid, El Youssef, Joseph, Tyler, Nichole, Castle, Jessica, Jacobs, Peter G. · 2019 · PLOS ONE

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 7 of the 23 sources its claims cite were checked for support.

Abstract

PURPOSE: We introduce two validated single (SH) and dual hormone (DH) mathematical models that represent an in-silico virtual patient population (VPP) for type 1 diabetes (T1D). The VPP can be used to evaluate automated insulin and glucagon delivery algorithms, so-called artificial pancreas (AP) algorithms that are currently being used to help people with T1D better manage their glucose levels. We present validation results comparing these virtual patients with true clinical patients undergoing AP control and demonstrate that the virtual patients behave similarly to people with T1D. METHODS: A single hormone virtual patient population (SH-VPP) was created that is comprised of eight differential equations that describe insulin kinetics, insulin dynamics and carbohydrate absorption. The parameters in this model that represent insulin sensitivity were statistically sampled from a normal distribution to create a population of virtual patients with different levels of insulin sensitivity. A dual hormone virtual patient population (DH-VPP) extended this SH-VPP by incorporating additional equations to represent glucagon kinetics and glucagon dynamics. The DH-VPP is comprised of thirteen differential equations and a parameter representing glucagon sensitivity, which was statistically sampled from a normal distribution to create virtual patients with different levels of glucagon sensitivity. We evaluated the SH-VPP and DH-VPP on a clinical data set of 20 people with T1D who participated in a 3.5-day outpatient AP study. Twenty virtual patients were matched with the 20 clinical patients by total daily insulin requirements and body weight. The identical meals given during the AP study were given to the virtual patients and the identical AP control algorithm that was used to control the glucose of the virtual patients was used on the clinical patients. We compared percent time in target range (70-180 mg/dL), time in hypoglycemia (<70 mg/dL) and time in hyperglycemia (>180 mg/dL) for both the virtual patients and the actual patients. RESULTS: The subjects in the SH-VPP performed similarly vs. the actual patients (time in range: 78.1 ± 5.1% vs. 74.3 ± 8.1%, p = 0.11; time in hypoglycemia: 3.4 ± 1.3% vs. 2.8 ± 1.7%, p = 0.23). The subjects in the DH-VPP also performed similarly vs. the actual patients (time in range: 75.6 ± 5.5% vs. 71.9 ± 10.9%, p = 0.13; time in hypoglycemia: 0.9 ± 0.8% vs. 1.3 ± 1%, p = 0.19). While the VPPs tended to over-estimate the time in range relative to actual patients, the difference was not statistically significant. CONCLUSIONS: We have verified that a SH-VPP and a DH-VPP performed comparably with actual patients undergoing AP control using an identical control algorithm. The SH-VPP and DH-VPP may be used as a simulator for pre-evaluation of T1D control algorithms.

Overview

CoChat Summary

TL;DR

The paper presents single-hormone and dual-hormone virtual patient populations for type 1 diabetes, built from glucoregulatory models with statistically sampled insulin and glucagon sensitivity parameters and an integrated aerobic exercise model. When matched to 20 clinical patients by total daily insulin requirement and weight and run under identical meals and the same artificial pancreas controller, the virtual populations showed no statistically significant differences in key glycemic outcomes.

Key findings

  • The single-hormone VPP performed similarly to actual patients: time in range 78.1 ± 5.1% vs. 74.3 ± 8.1% (p = 0.11), and time in hypoglycemia 3.4 ± 1.3% vs. 2.8 ± 1.7% (p = 0.23).
  • The dual-hormone VPP also performed similarly to actual patients: time in range 75.6 ± 5.5% vs. 71.9 ± 10.9% (p = 0.13), and time in hypoglycemia 0.9 ± 0.8% vs. 1.3 ± 1% (p = 0.19).
  • Time in hyperglycemia was not significantly different for SH-VPP (18.4 ± 5.3% vs. 22.9 ± 8.8%, p = 0.08) or DH-VPP (23.5 ± 5.7% vs. 26.7 ± 11.4%, p = 0.21).
  • In a comparison across 10 selected meal scenarios, the SH-VPP had lower mean absolute error for time in range relative to clinical data than the UVA/Padova simulator (15.8% vs. 33.4%).

Methods

  • The SH-VPP used eight differential equations for insulin kinetics, insulin dynamics, and carbohydrate absorption; the DH-VPP extended this to thirteen equations by adding glucagon kinetics and dynamics. Insulin sensitivity factors (Sf1, Sf2, Sf3) were statistically sampled for the SH-VPP; glucagon sensitivity and related parameters were also sampled for the DH-VPP.
  • Validation used clinical data from 20 people with T1D in two separate 3.5-day randomized outpatient artificial pancreas trials, with meals, daily activities, and in-clinic aerobic exercise at 60% of maximal VO2. Twenty virtual patients were matched to the 20 clinical patients by closest total daily insulin requirement and weight.
  • The identical meals and the same OHSU-FMPD control algorithm were applied to virtual patients, with ±30% meal uncertainty, circadian insulin sensitivity variability, and CGM noise modeled. Outcomes were compared using two-tailed t-tests at a 5% significance level, with mean absolute error reported.

Limitations

  • The paper states that meal amount was estimated rather than known, rescue carbohydrate timing was uncertain, circadian insulin sensitivity variability was modeled approximately, the exercise model assumed 50% active muscular mass for all subjects, and CGM noise was based on the Dexcom G4 sensor while clinical data used the Dexcom G5.
  • The paper states that mean absolute error was higher than preferred for time in range and time in hyperglycemia, indicating imperfect individual-level matching.
  • Evident from the text: validation used only one control algorithm and a relatively small clinical sample of 20 patients, so generalizability to other controllers or larger populations is not directly established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0217301

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Block diagram of the glucoregulatory model.
Fig 1 Block diagram of the glucoregulatory model.CC BY · PubMed Central
Fig 2 Estimated TDIR across Sc values. Sc of 0.4 was selected as the insulin sensitivity modifier for people with T1D for generating VPPs of people with an average weight of 76.3 kg.
Fig 2 Estimated TDIR across Sc values. Sc of 0.4 was selected as the insulin sensitivity modifier for people with T1D for generating VPPs of people with an average weight of 76.3 kg.CC BY · PubMed Central
Fig 3 Histogram of the TDIR values of the clinical patients (left), SH-VPP (middle) and DH-VPP (right).
Fig 3 Histogram of the TDIR values of the clinical patients (left), SH-VPP (middle) and DH-VPP (right).CC BY · PubMed Central
Fig 4 Simulated vs. actual glucose and insulin profiles of one representative subject in single-hormone trial. Both experiments were initialized at 8:00 am. Carbs are shown with circles. Filled circles show the start of exercise. Higher resolution data from this study is shown in Fig A in S1 File.
Fig 4 Simulated vs. actual glucose and insulin profiles of one representative subject in single-hormone trial. Both experiments were initialized at 8:00 am. Carbs are shown with circles. Filled circles show the start of exercise. Higher resolution data from this study is shown in Fig A in S1 File.CC BY · PubMed Central
Fig 5 Simulated vs. actual glucose, insulin and glucagon profiles of one representative subject in dual-hormone trial. Both experiments were initialized at 8:00 am. Carbs are shown with circles. Filled circles show the start of exercise. Higher resolution data from this study is shown in Fig B in S1 File.
Fig 5 Simulated vs. actual glucose, insulin and glucagon profiles of one representative subject in dual-hormone trial. Both experiments were initialized at 8:00 am. Carbs are shown with circles. Filled circles show the start of exercise. Higher resolution data from this study is shown in Fig B in S1 File.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 2 Not valid · 11 Not checked · 40 Own results and interpretations

30 more claims

Create a free account to see all 59 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 9
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Cited by

See all 79

Metadata

Authors
Resalat, N., El Youssef, J., Tyler, N., Castle, J., & Jacobs, P. G.
Affiliations
Oregon Health & Science University (US)
Corresponding author
Jacobs, Peter G.
Venue
PLOS ONE
Published
2019-07-25
Volume
14
Issue
7
Pages
e0217301
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2963898471
Cited by
78
References
28
Citations by year
2026: 6 · 2025: 11 · 2024: 10 · 2023: 19 · 2022: 8 · 2021: 11 · 2020: 10 · 2019: 2
FWCI
6.29
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (1DP3DK101044)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 1 diabetes, virtual patient population, artificial pancreas, closed-loop glucose control, insulin kinetics, exercise model, insulin sensitivity, glucagon sensitivity, glucose homeostasis, time in range, hypoglycemia, hyperglycemia, carbohydrate absorption
MeSH terms
Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glucagon, Humans, Insulin, Kinetics, Male, Middle Aged, Models, Biological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.